Acquiring Company
BioMarin Pharmaceutical
Acquired Company
Inozyme Pharma
San RafaelBostonBiotechnologyHealth CareMedicalGeneticsTherapeuticsHealthcareHealth CareTherapeuticsPharmaceuticalDescription
BioMarin Pharmaceutical Inc. has completed the acquisition of Inozyme Pharma, Inc. for $4.00 per share in an all-cash transaction valued at approximately $270 million. This acquisition will enhance BioMarin's enzyme therapies portfolio with the late-stage therapy INZ-701. Following the merger, Inozyme's shares will cease trading on the Nasdaq.
Quick answer
BioMarin Pharmaceutical is acquiring Inozyme Pharma, announced July 1, 2025. BioMarin Pharmaceutical is based in San Rafael, California, United States.
- How much did BioMarin Pharmaceutical pay for Inozyme Pharma?
- The deal value was not disclosed.
- What does BioMarin Pharmaceutical do?
- BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery.
- Where are BioMarin Pharmaceutical and Inozyme Pharma based?
- BioMarin Pharmaceutical is based in San Rafael, California, United States. Inozyme Pharma is based in Boston, Massachusetts, United States.
- Who are the decision-makers at BioMarin Pharmaceutical?
- Fundz holds 1 contact at BioMarin Pharmaceutical. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Genetics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Cerevel Therapeutics for $45 per share (May 28, 2025)
- Concentra to acquire Elevation Oncology, shut it down (June 20, 2025)
- Supernus acquires SAGE Therapeutics for USD 8.50/share (July 31, 2025)
- AbbVie to acquire Capstan Therapeutics (July 15, 2025)
- AbbVie to acquire Capstan Therapeutics for $2.1B, $2.1B (June 30, 2025)
- Esteve Pharmaceuticals acquires Caprelsa® from Sanofi (July 1, 2025)
Who to call at BioMarin Pharmaceutical, and when
When BioMarin Pharmaceutical changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day BioMarin Pharmaceutical raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioMarin Pharmaceutical, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioMarin Pharmaceutical. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BioMarin Pharmaceutical makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Inozyme Pharma?
Inozyme Pharma was acquired by BioMarin Pharmaceutical, based in San Rafael. The deal was reported on July 1, 2025. BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery. BioMarin Pharmaceutical is publicly traded (BMRN) and operates in Biotechnology.
When did BioMarin Pharmaceutical acquire Inozyme Pharma?
BioMarin Pharmaceutical's acquisition of Inozyme Pharma was reported on July 1, 2025. BioMarin Pharmaceutical Inc. has completed the acquisition of Inozyme Pharma, Inc. for $4.00 per share in an all-cash transaction valued at approximately $270 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Inozyme Pharma do?
Inozyme Pharma is a USA-based biopharma company focused on developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. The company aims to address significant unmet needs in patients suffering from these conditions. It is privately held, operating in Healthcare, and is based in Boston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.